Bionano_RGB.png
Bionano Announces Presentation of Optical Genome Mapping Utility Across Cancer Research Applications at the Cancer Genomics Consortium (CGC) 2024 Annual Meeting
01 août 2024 08h00 HE | Bionano Genomics
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- A sponsored exhibitor session will feature Dr. Phillip Michaels from Harvard Medical School and Brigham and Women’s Hospital presenting data from a...
Picture1.png
Scientific Presentations Highlight OGM’s Utility for Cancer Research at Joint Annual Meeting for Three Molecular and Cytogenetic Associations
02 juil. 2024 08h00 HE | Bionano Laboratories
At a sponsored workshop, Su Yang from The University of Texas MD Anderson Cancer Center will present case studies that demonstrate the ability of the optical genome mapping (OGM) workflow to detect...
Picture1.png
Bionano Laboratories Announces New Category I CPT Code for OGM Use in Hematological Malignancy Analysis
17 juin 2024 16h05 HE | Bionano Laboratories
American Medical Association issues Category I CPT code for the use of optical genome mapping in genome-wide analysis related to hematological malignancies
Bionano_RGB.png
Bionano Announces Series of Major Advancements to its Suite of Computational Tools for Comprehensive Cancer Analysis
09 mai 2024 08h00 HE | Bionano Genomics
Bionano announces significant advancements to its suite of computational tools for comprehensive cancer analysis.
logo.jpg
Correction: ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
18 oct. 2023 15h50 HE | ImCheck Therapeutics SAS
ImCheck to Present New Positive Data on ICT01 Monotherapyin Hematological Cancers at ESMO 2023 Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trialshow strong safety...
logo.jpg
ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
15 oct. 2023 18h05 HE | ImCheck Therapeutics SAS
ImCheck to Present New Positive Data on ICT01 Monotherapyin Hematological Cancers at ESMO 2023 Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trialshow strong safety...
rhizenhighres logo.png
Rhizen Pharmaceuticals S.A. and Curon Biopharmaceutical Limited Announce an Exclusive Licensing Agreement to Develop and Commercialize Tenalisib, a Dual PI3K Delta and Gamma Inhibitor for Oncology in Greater China
12 oct. 2020 08h00 HE | Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland and Shanghai, China. October 12, 2020, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S. A. (Rhizen), a Switzerland-based privately held clinical-stage...
Transparency Market Research
Hematological Malignancies Market to attain a valuation of US$51.9 billion by 2024 - TMR
19 mars 2019 08h45 HE | Transparency Market Research
Albany, New York, March 19, 2019 (GLOBE NEWSWIRE) -- The TMR report projects the global hematological malignancies market to register an impressive CAGR of 7.50% from 2016 to 2024. The market was...
Abstract från AroCel
Abstract från AroCell accepterad för posterpresentation under AACR 2019
28 févr. 2019 04h30 HE | AroCell AB
Ett abstract från AroCell har accepterats för posterpresentation på American Association of cancer Research 2019 (AACR 2019) som hålls mellan 29 mars och 3 april i Atlanta, Georgia, USA. Studien...
Abstract from AroCel
Abstract from AroCell accepted for poster presentation during AACR 2019
28 févr. 2019 04h30 HE | AroCell AB
An abstract from AroCell has been accepted for poster presentation on the American Association of Cancer Research 2019 (AACR 2019) held from March 29 to April 3 in Atlanta, Georgia, USA. The Study...